Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
Status:
Completed
Trial end date:
2018-04-09
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and the best dose of everolimus when given
together with bendamustine hydrochloride in treating patients with cancer of the blood
(hematologic cancer) that has returned after a period of improvement (relapsed) or did not
get better with a particular treatment (refractory). Everolimus may prevent cancer cells from
growing by blocking a protein that is needed for cell growth. Drugs used in chemotherapy,
such as bendamustine hydrochloride, work in different ways to stop the growth of cancer
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving everolimus together with bendamustine hydrochloride may be a better
treatment for hematologic cancer.